Jubilant Therapeutics Inc. receives Orphan Drug Designation for the PRMT5 inhibitor - JBI-778 for the treatment of Glioblastoma Multiforme (GBM) ...Middle East

BEDMINSTER, N.J., Feb. 13, 2023 /PRNewswire/ -- Jubilant Therapeutics Inc., a clinical stage biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced that the United States Food and Drug...

Hence then, the article about jubilant therapeutics inc receives orphan drug designation for the prmt5 inhibitor jbi 778 for the treatment of glioblastoma multiforme gbm was published today ( Monday 13/02/2023 - 04:37 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Jubilant Therapeutics Inc. receives Orphan Drug Designation for the PRMT5 inhibitor - JBI-778 for the treatment of Glioblastoma Multiforme (GBM) )

Also on site :

• This Guitarist Helped Shape One of the Most Iconic Sounds of the '90s
• 32 Years Ago Today, Iconic '90s Rocker Died at the Age of 27
• I Tried 19 Frozen Pizzas—And the Winner Is a New Find That Won by a Landslide